Extracellular factors that inhibit axon growth and intrinsic factors that promote it affect neural regeneration. Therapies targeting any single gene have not yet simultaneously optimized both types of factors. Chondroitin sulphate (CS), a glycosaminoglycan, is the most abundant extracellular inhibitor of axon growth. Here we show that mice carrying a gene knockout for CS N-acetylgalactosaminyltransferase-1 (T1), a key enzyme in CS biosynthesis, recover more completely from spinal cord injury than wild-type mice and even chondroitinase ABC-treated mice. Notably, synthesis of heparan sulphate (HS), a glycosaminoglycan promoting axonal growth, is also upregulated in TI knockout mice because HS-synthesis enzymes are induced in the mutant neurons. Moreover, chondroitinase ABC treatment never induces HS upregulation. Taken together, our results indicate that regulation of a single gene, T1, mediates excellent recovery from spinal cord injury by optimizing counteracting effectors of axon regeneration—an extracellular inhibitor of CS and intrinsic promoters, namely, HS-synthesis enzymes.
Many patients with spinal cord injury (SCI) suffer from severe paralysis1,2, possibly because injured axons in the adult mammalian central nervous system (CNS), including those in humans, rarely regenerate1,2. Recent findings demonstrate that the regulation of both extracellular and intrinsic factors that affect axon regeneration is essential to recovery from adult CNS neuronal injury3,4. Reduction or overexpression of intracellular cell-autonomous regulators promotes axon regrowth5,6,7,8,9,10,11; however, controlled manipulation of the endogenous expression of these molecules is challenging8. Regrettably, current protocols for removing or reducing the extracellular inhibitors do not result in axon regeneration sufficient for complete recovery from SCI.
Chondroitin sulphate (CS), a glycosaminoglycan (GAG) produced mainly by reactive astrocytes and partly by NG2 proteoglycan-positive cells after SCI, is the most widely distributed and most potent inhibitor of axon regeneration3,5,6,7,12. CS degradation resulting from application of chondroitinase ABC (ChABC), a bacterial enzyme, to the injury site promotes some additional axon regeneration6. Many practical methods can effectively provide ChABC near injury sites; notably, methods involving viral vector delivery of ChABC13,14,15 result in more axon sprouting16 (see reviews17,18). In addition, we must consider treatment alternatives; specifically, we must recognize that CS may be physiologically necessary to minimize the inflammation and limit its area after SCI by inhibiting invasion of macrophages19,20. Thus, complete removal of CS may exacerbate, not ameliorate, SCI.
Here we focused on optimizing CS synthesis following SCI. The process of the CS synthesis is very complicated, and more than 10 enzymes participate in CS synthesis21,22,23 (Fig. 1a). Notably, heparan sulphate (HS) is also a GAG and a potent promoter of axonal growth, and the first enzymatic step of CS synthesis and of HS synthesis are the same24. Therefore, the second step in CS synthesis, catalysed by CS N-acetylgalactosaminyltransferase-1 (abbreviated as T1 in this paper), is the first unique and rate-limiting step in CS synthesis; consequently, T1 is tightly regulated because it begins CS-specific polysaccharide chain synthesis24,25,26,27,28.
Here we generated T1-knockout (T1KO) mice29 and induced SCI in these and wild-type (WT) mice to investigate the mechanism of recovery from compression-induced (70 kdyne impact force) SCI. T1KO mice exhibited significantly better recovery from SCI based on locomotor behaviours and histological analysis than did untreated WT or ChABC-treated WT mice. Synthesis of HS, as also upregulated in T1KO mice because expression of HS-synthesis enzymes was induced. Notably, ChABC treatment never induced HS upregulation. Judging from our results and those from two previous reports, an HS-synthesizing enzyme Ext2 satisfies the definition of a potential intrinsic growth regulator in neurons30,31. Our results indicate that a single gene, that encodes T1, is a promising therapeutic target for SCI treatment.
T1KO recover more rapidly than WT and ChABC-treated mice
We had focused on optimizing CS synthesis following SCI. However, the formation of a tetrasaccharide linker is notably the first step in both CS and HS biosynthesis, and CS inhibits axonal regrowth, whereas HS promotes it (Fig. 1a). Therefore, the second step in CS and HS synthesis—which is catalysed by T1 and the Ext1-Ext2 heterodimer (Ext1/Ex2), respectively—is the first unique and rate-limiting step in each pathway. These enzymes share a substrate, the tetrasaccharide linker21, and they bifurcate GAG synthesis into two alternative pathways24,26. Although CS N-acetylgalactosaminyltransferase-2 (CSGalNAcT2; abbreviated as T2 in this paper) is a T1 isoform, it has lower enzyme activity than does T121,27.
We focused on reducing T1 activity, via gene knockout, as a potential treatment for SCI. T1KO mice are viable, but they have abnormal bone development and 10% shorter bodies than do WT mice29 (see Supplementary Fig. S1a–c). Following induced SCI, we examined and compared the recoveries of T1KO, T2-knockout (T2KO), untreated WT and ChABC-treated WT mice. Recovery of motor functions following SCI was evaluated using the Basso mouse scale (BMS) scoring32 (Fig. 1b), footfall tests (Fig. 1c; Supplementary Movie 1), footprint analysis (Supplementary Fig. S2a,b) and electromyography (Supplementary Fig. S2c); T1KO mice recovered from SCI more quickly and more completely than did T2KO, ChABC-treated WT or untreated WT mice (Fig. 1b,c; also see Supplementary Fig. S2d,e). The areas encompassing serotonin-positive (5HT(+)) terminals1 beyond the lesion site were much larger in T1KO than in untreated WT or ChABC-treated WT mice (Fig. 1d, Table 1 and Supplementary Fig. S2f,g), and there were many more 5HT(+) terminals in T1KO mice (Table 1; see also Supplementary Fig. S2f,g). These observations indicated that functional recovery after SCI was associated with axon regrowth and/or sprouting (Fig. 1d and Table 1) in T1KO mice. Importantly, these effects in T1KO mice were superior to those following ChABC treatment (Table 1 and Supplementary Fig. S2g), and T2KO mice did not show any significant increase in 5HT(+) staining (Fig. 1e and Supplementary Fig. S2f,g). To determine whether the corticospinal tract (CST; a representative pathway operating voluntary movement) recovered, we traced the biotinylated dextran amine (BDA) (+)-extending axons in each group of mice after SCI. Axons that had migrated past a scar (Supplementary Fig. S3a,b) and into caudal regions were evident only in T1KO SCI mice (Supplementary Fig. S3b). GAP-43 immunoreactivity—which is a marker of neuron growth, growth cones and extending axons14,33—was evident in CST axons in caudal regions only in T1KO SCI mice, but not in ChABC-treated WT or T2KO SCI mice (Supplementary Fig. S3c). Following SCI, caudal GAP-43(+)-CST axon terminals were significantly more abundant in T1KO SCI mice than in WT or T2KO mice (Supplementary Fig. S3d,e).
Next, we examined whether the superior recovery and axon regrowth in T1KO animals depended on reduction of CS. We used immunohistochemistry to confirm that ChABC treatment broke CS down (Supplementary Fig. S4a). T1 was highly expressed in some reactive astrocytes in WT mice following SCI, but it was not evident in T1KO mice (Supplementary Fig. S4b). Moreover, CS production in areas with glial scars, which are produced by reactive astrocytes3, was much lower in T1KO mice than WT or T2KO mice (Fig. 2a). We also demonstrated biochemically (Fig. 2b) and using morphometrical measurements (Fig. 2c) that CS levels in injured spinal cords of T1KO mice were lower than in those of WT or T2KO mice (Supplementary Fig. S4c). Undoubtedly, several other enzymes are involved in CS synthesis28 (cf. Fig. 1a), and CS is not completely absent from T1KO mice29 (Fig. 2c; Supplementary Fig. S4d). Notably, Caenorhabditis elegans lacks T1 and T2, yet a chondroitin backbone comprising GalNAc and GlcA is synthesized in worms by four other enzymes (ChSy1–3 and Chpf2) that are also found in mammals34 (see Fig. 1a); therefore, these four enzymes may synthesize CS in mammals lacking T1, although probably at a much slower rate than when T1 is present. Nevertheless, fibrotic scars (Fig. 3a) and glial scars3,19,20 (Fig. 3b) were much smaller in T1KO mice than in WT or ChABC-treated mice (Fig. 3a,b; Supplementary Fig S3a). In contrast, scar area did not differ significantly between ChABC-treated and WT mice (Fig. 3a,b). Each glial scar in T1KO mice was limited to a narrow area that surrounded the centre of the SCI lesion (Fig. 3c; Supplementary Fig. S3a). 5HT(+) terminals in T1KO mice were highly concentrated around the astrocytes but scars in ChABC-treated mice were not (Fig. 3d). These results indicated that both effects of T1KO—more complete axon regrowth and more regrowing axon terminals (Fig. 1b–d, and Table 1)—were related to a reduction in the ‘barrier’ scar area and that this reduction was a result of decreased CS production3,6,7 (Figs 2 and 3). Moreover, each effect was probably independent of residual CS in T1KO mice because ChABC treatment caused more CS degradation and led to worse outcomes than did T1KO (Fig. 3a,b and Table 1). ChABC treatment reportedly reduces the perineuronal net (PNN), which is enriched with CS and inhibits neural plasticity35; moreover, reductions in the PNN reportedly enhance neuronal plasticity, neuronal sprouting and recovery from SCI36,37. Therefore, we examined the PNN in mice recovering from induced SCI. We used Wisteria floribunda agglutinin (WFA), a generalized marker of PNN, to assess PNNs and found that WFA was evident in WT mice but not in T1KO mice (Fig. 3e–g).
Increased HS synthesis in T1KO mice promotes rapid recovery
On the basis of histological and phenotypic features of T1KO mice, we doubted that the 25% reduction in CS (Fig. 2c) in T1KO mice was solely responsible for such complete recovery from SCI (Fig. 1b–d, Table 1 and Supplementary Fig. S2a,b,d,e,g). Therefore, we suspected that changes in HS synthesis might also be involved because T1 and some HS-synthesis enzymes share the tetrasaccharide linker as a substrate24,28 (Fig. 1a). The expression of enzymes other than T1 that synthesize CS in response to SCI was not significantly different between injured T1KO and injured WT mice (Supplementary Fig. S5a). Surprisingly, however, the expression of HS-synthesis enzymes—including Ext1 and Ext2, which are essential to HS synthesis (Fig. 1a)—was much higher in injured T1KO mice than that in uninjured T1KO or injured WT mice (Fig. 4a). Importantly, ChABC treatment did not cause upregulation of these HS-synthesis enzymes (Supplementary Fig. S6a).
On the basis of these results, we strongly suspected that HS synthesis contributed to the superior recovery of T1KO mice; therefore, we examined HS expression after SCI. HS-positive areas were significantly larger in the injured spinal cords of T1KO mice than in those of WT mice (Fig. 4b), and HS levels were 20-fold higher in the injured regions of T1KO mice than in those of WT (Fig. 4c; Supplementary Fig. S6b). Notably, neither ChABC treatment nor T2 knockout increased HS levels (Fig. 4b,d; Supplementary Fig. S6c). There were no significant differences between injured T1KO and injured WT mice in the expression of any CS-containing proteoglycan (CSPG) or syndecan-3, which is an HS-containing proteoglycan (HSPG; Supplementary Fig. S6a,d). To assess whether this upregulation of HS synthesis in T1KO mice following SCI promoted axon regrowth or sprouting, we examined the effects of continuously administered bacterial heparitinase (HSase), which degrades HS30, on recovery from SCI. On the basis of BMS scoring (Fig. 5a) and footfall tests (Fig. 5b), HSase treatment slowed the recovery of T1KO mice (Fig. 5 and Table 2), as did RNA interference (RNAi)-mediated knockdown (KD) of an HS-synthesis enzyme, Ext1 (Fig. 5 and Table 2). In addition, HSase treatment reduced the area encompassing regenerating 5HT(+) axon terminals in T1KO mice to a level similar to that in WT mice (Table 2), but the recovery in ChABC-treated mice was not sensitive to HSase, suggesting that ChABC did not induce HS upregulation (Supplementary Fig. S6a,e). These results indicated that upregulation of HS synthesis in T1KO mice promoted axon regrowth and/or sprouting and functional recovery from SCI, just as it promotes axon growth during CNS development5,25.
We tried to identify the target HSPGs in injured T1KO mice that bore the upregulated HSase-sensitive HS. HS-modified syndecan-3 (N-syndecan) and glypican-1 were highly expressed (Fig. 6a and Supplementary Fig. S6d) and widely distributed (Fig. 6b) at sites of SCI in T1KO mice. In the injured spinal cords of T1KO mice, both HSPGs were detected via HS-specific antibodies (Fig. 6c) and had HSase-sensitive HS chains (Fig. 6d); importantly, in WT SCI mice, degraded HS derived from these two HSPGs was barely evident, indicating that the upregulated HSase-sensitive HS was specifically bound to syndecan-3 and glypican-1 in injured T1KO (Fig. 6d).
After SCI, Ext2 was expressed in neurons30 of T1KO mice (Fig. 7a), and the expression of HS-synthesis enzymes was upregulated in neuron-rich areas rather than in areas of glial scarring (Fig. 7b); therefore, we concluded that extra HS was produced by the neurons5,24,25 that expressed HS-synthesis enzymes such as Ext2. Receptor protein tyrosine phosphatase-σ (RPTPσ), a receptor for both HSPGs and CSPGs38,39, was also upregulated in T1KO mice after SCI, and RPTPσ co-localized with some of the regrowing and/or sprouting axons (Supplementary Fig. S7a–d). HS, unlike CS, is known to promote axon growth during neural development5,24,25,31,39; therefore, our data indicated that GAG synthesis in T1KO mice was more favourable to axon regrowth than was the GAG synthesis in WT mice. To assess whether upregulation of HS was directly involved in neurite growth following SCI and whether effects of RPTPσ on neurite growth depended on HS, we examined the effects of concurrent overexpression of Ext1 and Ext2 on cultured neurons (Fig. 7c). Ext1-Ext2 overexpression induced neurite growth in an HSase-sensitive (Fig. 7c) and RPTPσ-sensitive (Supplementary Fig. S7e) manner39, indicating that upregulation of HS contributed to axon growth. Therefore, HS-synthesis enzymes such as Ext2 may promote axon growth intrinsically in neurons by targeting new HS synthesis to syndecan-3, glypican-1 or both40. RPTPσ messenger RNA expression and RPTPσ levels were elevated in WT, ChABC-treated and T1KO mice (Supplementary Fig. S7c,d), indicating that at least the increased axon regrowth was not due to a RPTPσ-dependent reduction in CS.
RNAi-mediated T1 KD (T1-KD) in vivo led to excellent recovery from SCI (Supplementary Fig. S8a–e). T1-KD-associated scars were similar in size to T1KO-associated scars (Supplementary Fig. S8f). T1-KD caused reduced CS synthesis (Supplementary Fig. S8g), and scar sizes were significantly smaller following T1-KD than following ChABC treatment (Supplementary Fig. S8h). Moreover, downregulation of CS synthesis and upregulation of HS-synthesis enzymes were induced by simultaneous T1-KD and T2-KD, as well as by T1KO (Supplementary Fig. S9a–c and Fig. 4, also see Supplementary Fig. S5a,b); notably, T1-KD alone was insufficient to cause both effects (Supplementary Fig. S9c,d; compared with Supplementary Fig. S9a,b).
T1KO mice had significantly better recovery from SCI than did WT or ChABC-treated mice (Fig. 1b–d); three distinct phenomena were responsible for this superior recovery. First, T1KO reduced CS synthesis and resulted in smaller scars than did ChABC treatment; reduced scaring probably contributed to better recovery because the smaller scars introduced smaller physical and weaker chemical barriers to the regrowing or the sprouting axons (Figs 1e, 2c and 3a–d, and Supplementary Fig. S2f). In addition, T1KO probably reduced CS concentrations (Fig. 3e). Notably, reduction of CS was apparently superior to complete elimination of CS for SCI recovery, probably because CS has some positive roles in recovery (Fig. 8a). Second, simultaneous upregulation of HS synthesis and downregulation of CS in T1KO mice were essential to excellent recovery from SCI. HS promotes axon growth5,24,25, and syndecan-3, a target HSPG of SCI-induced HS upregulation, is enriched in axons and the extracellular matrix around axons41. T1KO and T1-KD+T2-KD (Supplementary Fig. S9c) produced the most favourable environment for recovery from SCI; specifically, these treatments shifted conditions at the injury away from the non-permissive CS-rich state (Fig. 8a,b). It is evident that T1KO was substantially superior to ChABC treatment specifically because HS synthesis was stimulated by T1KO and never by ChABC treatment (Fig. 5a,b, Table 2 and Supplementary Fig. S5a,d). HSPGs are important for signal transduction, axon growth and axon guidance24,42; therefore, our findings are very important to axon regeneration. Third, expression of HS chains on both syndecan-3 and glypican-1 and expression of HS-synthesis enzymes (for example, Ext2, Ext1 and Extl2) in neurons were essential to the superior recovery from SCI of T1KO mice (Figs 4a,d, 6a,c and 7a,b). Taken together, our results and those from two previous reports indicated that Ext2 satisfies the definition of a potential intrinsic growth regulator in neurons; the most relevant findings are that Ext1/2 expression is developmentally downregulated in the CNS43 and that Ext2 and syndecan-1 expressions in neurons are specifically upregulated during peripheral nerve regeneration30. Lack of T1 evidently induced these intrinsic positive regulators of axon growth4,10. These HS-synthesis enzymes belong to a newly identified group of ‘development-dependent factors with axon growth-promoting features’ and are totally different from previously described factors such as PTEN and KLFs9,11. Therefore, we conclude that T1KO and ChABC treatment led to recovery from SCI by very distinct mechanisms.
The following two strategies for controlling CS synthesis have been developed: first, a deoxyribozyme targeting Xylt1 (see Fig. 1a) messenger RNA inhibits synthesis of the first residue of the tetrasaccharide linker44,45. Second, genetic ablation of Sox9, a transcription factor, inhibits expression of some CS-synthesizing enzymes (for example, Xylt1/2 and C4st1)46. Each strategy is effective in inhibiting CS synthesis and in improving recovery from SCI. However, based on our new findings, inhibition of T1 should be better than either of those strategies because both of those strategies should inhibit HS synthesis, and HS synthesis promotes axon growth.
In conclusion, our results demonstrate that knocking out a single enzyme, T1, caused both reduced CS synthesis and increased HS synthesis and that manipulation of this single enzyme resulted in the reduction of extracellular inhibitors and the induction of intrinsic growth promoters of axon regeneration. Therefore, our findings provide a novel principle for development of axon regeneration strategies. Chemicals that specifically inhibit T1 might be effective treatments for SCI; however, we need to know the molecular mechanisms by which neuronal HS-synthesis genes (for example, Ext2) were upregulated in T1KO mice. Finally, adding inhibition of TI to other treatments36,47 for SCI may improve overall clinical outcomes.
ChABC and HSase (HSase I/III), heparanase I and II, WFA and AteloGene Local Use Kits for atelocollagen-mediated in vivo short interfering RNA were purchased from Seikagaku Corp. (Tokyo, Japan), from IBEX Technology Inc. (Montreal, Canada), Vector Laboratories Inc. (Burlingame, CA, USA) and from KOKEN Co. Ltd. (Tokyo, Japan), respectively. An osmotic minipump (Model 2006 (for 7W long) and Model 2004 (for 4W long)), catheter tubing (Mit-02) and the infusion kit were purchased from ALZET (Cupertino, CA). Antibodies used in this study are listed in Supplementary Table S1 (As for the two antibodies provided from other researchers, listed in this Table, please refer to refs 48, 49).
Generation of T2KO
All animal experimental studies were conducted with the approval of the Animal Care and Use Committee of Niigata University. T1KO29 mice were derived from the C57BL/6N strain. For most experiments, the WT strain used was C57BL/6N; the ICR strain was used only for the in vivo RNAi studies. T2KO mice were generated via the methods used to generate T1KO mice31. The mouse T2 gene was identified as NM_030165. Exon 5 of mouse T2 encodes a DXD motif, which is a binding site for Mn2+ that is essential to the in vitro activity of most GalNAc/Gal transferases50; therefore, we designed a targeting vector with the mouse T2 exon 5 located between two loxP sites (Supplementary Fig. S1a). The T2KO mice were generated using an embryonic stem (ES) cell line derived from C57BL/6N mice; this line is designated RENKA. Resulting chimeric mice were mated to C57BL/6N mice and heterozygous offspring (CSGalNAcT2+/flox(neo)) were mated to telencephalin-cre mice29.
Induction of SCI
Mice (8–10 weeks old, C57BL/6J, male) were subject to compression-induced SCI; a bilateral contusion injury was induced at the 10th thoracic vertebrae (Th10) of individual mice with a commercially available SCI device (Infinite Horizon Impactor; Precision Systems and Instrumentation, Lexington, NY)20,32, except that here we used a 70-kdyne impact force. The device reports data regarding time versus force and time versus displacement. The locomotor recovery assessment was performed using video recording32, and BMS open-field scoring was used to test mice once weekly for functional recovery during the 6–8 weeks following SCI32. The evaluations were scored independently by two investigators who were unaware of the experimental groups (at least eight mice in each group). On the third day after induction of SCI, mice were excluded if they had an incomplete injury (BMS score>0 on that day). Morphometric assays were performed using SCI samples prepared from the sagittal sections at 12 μm intervals32.
For each footfall test, a mouse was placed on a wire mesh grid and videotaped for 5 min while on the grid. To be scored, an animal had to walk for a minimum of 3 of the 5 min as determined by three independent examiners; for each animal scored, the total number of the footfalls from the bars was counted, and the total walking time was recorded.
To assess stepping patterns of hind limbs during forward locomotion after injury, the bottom of a well-lit runway (3 cm wide and 100 cm long) was lined with white paper, and mice were required to run along the runway in a darkened box. To record footprints, the planter surfaces of hind limbs were brushed with ink during continuous locomotion across a paper.
The electrophysiological experiments to evaluate motor function resulting from evoked potential of the neuromuscular function were performed by short trains of five square-wave stimuli of 0.5 ms duration with an interstimulus interval of 3 ms (ref. 32). The active and the reference electrodes were placed in the muscle belly, and near the distal tendon of the muscle in each limb32, respectively. Scorps3 software (AD Instruments, New South Wales, Australia) was used to average and analyse 100 responses including the latency period.
Quantitative real-time PCR
Total RNA was extracted from the SCI regions using an RNeasy FFPE kit or an ALL prep RNA kit (QIAGEN). Total RNA (0.5 μg) was used as template; the iScript one-step RT-PCR kit (Bio-Rad), the SsoFast Probes supermix (Bio-Rad) and the PrimeTime qPCR assay (Integrated DNA Technologies, IW) were use for real-time reverse transcriptase–PCR; the reaction parameters were as follows: 95 °C for 30 s; and 40 cycles at 95 °C for 2 s and 65 °C for 5 s; 65–95 °C for 2 s) as indicated in the Taqman probe (Life Technologies) gene expression assay materials. Nucleotide sequence of real-time quantitative PCR primers and ZEN double-quenched probes are listed in Supplementary Table S2.
In vivo RNAi after SCI
For the in vivo RNAi studies, SCI was induced in ICR mice (8–10 w; Clea Japan, Inc.) with the IH impactor as described above except that the impact force was 100 kdynes. Just after the SCI contusion, gelfoam impregnated with a mixture containing one or two siRNAs (10 μM each) and AteloGene Local Use Kit (see Materials) was placed on the lesion area51,52,53. RNA sequences of the siRNAs used in these experiments are listed in Supplementary Table S354. The scrambled sequences of the negative-control siRNAs had four or five nucleotides that differed from the corresponding nucleotides in the targeted siRNAs.
ChABC and HSase treatments in vivo
Continuous ChABC treatment after SCI was performed using an osmotic pump14,55 set at the 10th thoracic vertebrae levels for up to 2 weeks (200 U ml−1 in a volume of 0.2 ml). For the HSase application, an osmotic minipump (ALZET, Cupertino, CA; Model 2006) was implanted subcutaneously and used to infuse HSase (0.2 unit per 6 μg) dissolved in saline containing 0.05% BSA or vehicle into the contusion site through a flexible plastic cannula because HSase is less stable than ChABC in vivo.
The dilution ratios for each antibody are listed in Supplementary Table S1. Tissue sections were incubated with biotinylated secondary antibody and then with avidin–biotin peroxide complex55,56 (Vectastain ABC kit; Vector Laboratories Inc.). Digital images were taken with a confocal laser scanning microscope (Zeiss, LSM5 exciter) and AxioVision charge-coupled device camera (Carl Zeiss). Spinal cord cryosections (20 μm thick) were obtained from mice that had been transcardially perfused with 4% formaldehyde. Standardized areas for sampling32 in the central regions (10 sections) were calculated using Image J (NIH) and MetaMorph (Molecular Devices). For analysis of 5HT(+) sprouting axons and boutons, rectangular areas were set 1–3 mm distal to the central line of the lesion site in each section32, and 10 sagittal sections from each mouse were used for quantitative analysis.
Anterograde labelling of the CST
Exactly 8 weeks after injury, BDA (10% in saline, molecular weight 10,000 Da; Molecular probes)6 was injected into the motor cortices to label the descending CST fibres. The injection site was precisely 2.1 mm posterior to the bregma, 2 mm lateral to the bregma and 0.7 mm deep. We performed pressurized injections with a glass capillary attached to a microsyringe (Narishige) at a rate of 0.1 μl min−1 until the desired amount was injected. Exactly 2 weeks after each injection, the animals were anaesthetized and perfused with PBS and then with 4% paraformaldehyde in PBS. We used Alexa Fluor 488-conjugated streptavidin (Invitrogen) and the Vectastain ABC Elite kit (Vector Laboratories Inc.) or a tyramide signal amplification fluorescence system (Perkin Elmer) to fluorescently label the BDA.
Quantification analysis of GAGs from the spinal cord
GAG analyses were conducted by enzymatic treatment and HPLC-based quantification29,57. GAGs were extracted from spinal cord tissue samples by incubating the samples in a protease solution (0.01 mg actinase E, 10 mM CaCl2, 50 mM Tris–HCl (pH 8.0)) at 55 °C for 2 days. After addition of trichloroacetate, each extract was centrifuged at 15,000 g for 20 min. Each partially purified CSPG and HSPG fractions was digested with ChABC (5 mIU ChABC in 60 mM CH3COONa, 50 mM Tris–HCl (pH 8.0)) or HSase (0.5 mIU HSase in 20 mM CH3COONa, 2 mM (CH3COO)2Ca (pH 7.0)), respectively. GAGs in each digests were derivatized using 2-aminobenzamide; these mixtures were analysed using HPLC (column: YMC pack PA, elution: 16–530 mM NaH2PO4)57.
Neuronal cell culture
Cortical neurons were prepared from embryonic day 17 or postnatal day 1 mice33, and were then transfected with a human Ext1 construct in a pCMVvector (Takara Bio Co., Otsu, Japan), a human Ext2 construct in the pcDNA3.1 vector (Invitrogen) or a combination thereof. Stealth Select RNAi (Invitrogen, s72517, s72516 and s72518) was used to knockdown RPTPσ expression. In some cultures, ChABC (2 mU) or HSase (2 mU) was added 12 h after transfection. Cells were stained with anti-HS 10E4 antibody 48 h after transfection. The sequences of siRNAs targeting RPTPσ are listed in Supplementary Table S3. siRNAs with scrambled sequence (Invitrogen) were used as negative controls.
Data are presented as mean values±s.e.m. Prism version 5.04 software (GraphPad) or SPSS statistics software (IBM) were used for to perform statistical analyses. Unpaired two-tailed Student’s t-tests were used for single comparisons. Analysis of variance (ANOVA; one-way, two-way or repeated-measures ANOVA) were used for multiple comparisons; Bonferroni’s procedure were used to assess post hoc pairwise differences. Repeated-measures ANOVA was used to analyse BMS and footfall scores with follow-up comparison of treatments for each day, by contrast t-test and correction for multiple comparisons by the Holm method (P=0.05). Each investigator was blinded with regard to genotypes during all procedures performed to collect data for subsequent statistical analysis. For analyses of the morphometric data, all evaluations were performed by ANOVA with post hoc-independent pairwise analysis. P<0.05 was considered statistically significant. The specific tests used to analyse data from each set of experiments are indicated in the figure legends.
How to cite this article: Takeuchi, K. et al. Chondroitin sulphate N-acetylgalactosaminyltransferase-1 inhibits recovery from neural injury. Nat. Commun. 4:2740 doi:10.1038/ncomms3740 (2013).
We thank M. Nakamura, T. Yamashita, M. Abematsu and K. Nakashima for instruction and advice on the SCI experiments; T. Shirasawa and M.L. Tremblay for antibodies; and I. Hasegawa and Y. Tada-Kinoshita for technical assistance. Generation of the T1KO and T2KO mice was supported by the TOGONO support group from the MEXT of Japan, and some antibodies were produced by Everest Biotech Ltd. (Upper Heyford, UK) for its Antibody award. This work was supported in part by KAKENHI (#17023019, #22022040 and #24111515 to M.I., #23592161 and #24110503 to K.T. and #23700440 to S.H.O.), Project Promoting Grants from Niigata University to M.I. and Agri-Health Translational Research Project support (#4300) from Ministry of the Agriculture, Forestry and Fisheries of Japan to K.T. Post-doctoral grants from JSPS supported N.Y. and Y.W.
Video of motor function recovery after SCI. WT and T1KO mice 4 weeks after SCI. The mice were placed on a steel net and the recovery of the walk was recorded. Note that the T1KO mouse walked much smoother than the WT mouse.
This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. To view a copy of this licence visit http://creativecommons.org/licenses/by/3.0/.